Published in Ann Oncol on May 10, 2013
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies | NCT00162123
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol (2015) 5.49
Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol (2015) 4.25
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol (2014) 1.63
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med (2014) 1.59
What have we learned from cancer immunotherapy in the last 3 years? J Transl Med (2014) 1.52
Cancer: Antitumour immunity gets a boost. Nature (2014) 1.28
Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. J Exp Med (2016) 1.24
Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol (2014) 1.11
Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med (2014) 1.06
Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunol Res (2014) 1.06
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov (2016) 1.06
Inhibitory Receptors Beyond T Cell Exhaustion. Front Immunol (2015) 1.05
AACR Cancer Progress Report 2014. Clin Cancer Res (2014) 1.05
VISTA is an immune checkpoint molecule for human T cells. Cancer Res (2014) 1.03
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer (2015) 1.03
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther (2015) 0.99
Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther (2014) 0.98
The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol (2014) 0.95
Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther (2014) 0.92
Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol (2015) 0.87
25-Hydroxyvitamin D2 /D3 levels and factors associated with systemic inflammation and melanoma survival in the Leeds Melanoma Cohort. Int J Cancer (2014) 0.85
Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells. Front Oncol (2014) 0.85
Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med (2016) 0.84
The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother (2015) 0.84
Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. Expert Rev Clin Immunol (2014) 0.84
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Med (2015) 0.83
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. Oncoimmunology (2015) 0.81
Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. EBioMedicine (2017) 0.81
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. Clin Cancer Res (2015) 0.80
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med (2014) 0.80
Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Ther Adv Med Oncol (2015) 0.78
T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. J Clin Oncol (2016) 0.78
Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study. J Immunother Cancer (2015) 0.77
Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment. Cancer Biother Radiopharm (2015) 0.77
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. Clin Cancer Res (2016) 0.76
Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma. J Skin Cancer (2013) 0.76
Pharmacological interventions for melanoma: Comparative analysis using bayesian meta-analysis. Oncotarget (2016) 0.75
Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy. Cancer Biol Ther (2013) 0.75
The prognostic value of cytotoxic T-lymphocyte antigen 4 in cancers: a systematic review and meta-analysis. Sci Rep (2017) 0.75
Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy. Cancer Immunol Res (2015) 0.75
Immunotherapy in genitourinary malignancies. Curr Opin Urol (2016) 0.75
Malignant Melanoma. Healthcare (Basel) (2013) 0.75
Extracting tumor tissue immune status from expression profiles: correlating renal cancer prognosis with tumor-associated immunome. Oncotarget (2015) 0.75
Exudative Polymorphous Vitelliform Retinopathy: Importance of Early Recognition of the Condition in Patients with Metastatic Melanoma. Ophthalmol Ther (2016) 0.75
Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infection. PLoS One (2015) 0.75
A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma. Oncoimmunology (2014) 0.75
Opposing effects of immunotherapy in melanoma using multisubtype interferon-alpha - can tumor immune escape after immunotherapy accelerate disease progression? Oncoimmunology (2015) 0.75
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study. Oncoimmunology (2015) 0.75
Epigenetics in Cancer: A Hematological Perspective. PLoS Genet (2016) 0.75
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. Breast Care (Basel) (2016) 0.75
The occurrence of non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma among metastatic melanoma patients: an observational cohort study in Denmark. BMC Cancer (2016) 0.75
Immune checkpoint blockade for hematologic malignancies: a review. Stem Cell Investig (2017) 0.75
Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res (2009) 5.99
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol (2010) 5.91
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res (2012) 4.56
Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol (2008) 4.23
Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest (2008) 3.69
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol (2010) 2.51
Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res (2011) 1.35
Upcoming strategies for the treatment of metastatic melanoma. Arch Dermatol Res (2012) 1.22
Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol (2010) 1.13
Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial. J Immunother (2012) 0.94
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst (1994) 7.20
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 6.36
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med (1999) 6.09
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol (2010) 5.91
Infections caused by Mycobacterium avium complex in immunocompromised patients: diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristics. J Clin Microbiol (1985) 5.22
Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med (2000) 4.32
Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells. N Engl J Med (1975) 3.81
Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol (1999) 2.77
Mouse ENU mutagenesis. Hum Mol Genet (1999) 2.72
Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A (1994) 2.61
Genetic analysis using genomic representations. Proc Natl Acad Sci U S A (1998) 2.52
Complexity of terminal airspace geometry assessed by lung computed tomography in normal subjects and patients with chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A (1999) 2.38
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol (2013) 2.35
Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab (1994) 2.22
Body mass index in male patients with COPD: correlation with low attenuation areas on CT. Thorax (2008) 2.12
The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. Cancer Res (2001) 2.03
Relation between increase in length of hip axis in older women between 1950s and 1990s and increase in age specific rates of hip fracture. BMJ (1994) 2.03
High sensitivity C-reactive protein in asthma. Eur Respir J (2006) 1.91
Human herpesvirus 8-associated hemophagocytic lymphohistiocytosis in human immunodeficiency virus-infected patients. Clin Infect Dis (2003) 1.72
Effects of ENU dosage on mouse strains. Mamm Genome (2000) 1.69
Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab (1993) 1.65
Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proc Natl Acad Sci U S A (2001) 1.65
Whole-body 18 FDG PET/CT imaging for lymph node and metastatic staging of conjunctival melanoma. Br J Ophthalmol (2008) 1.61
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol (2007) 1.58
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol (2000) 1.57
Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA (1988) 1.56
Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol (2001) 1.54
The mutagenic action of N-ethyl-N-nitrosourea in the mouse. Mamm Genome (2000) 1.53
Impaired cough reflex in patients with recurrent pneumonia. Thorax (2003) 1.53
Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann Oncol (2001) 1.52
Pityriasis rosea and human herpesvirus 7, a true association? Dermatology (1998) 1.44
Small-bowel metastasis of malignant melanoma: video capsule endoscopy appearance. Endoscopy (2010) 1.44
Anti-peripheral myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibody by complement component 1 fixation. Proc Natl Acad Sci U S A (1985) 1.42
Appraisal of a new rapid enzyme strip. Med J Aust (1980) 1.40
Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR). J Immunother (1999) 1.37
Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol (2011) 1.37
Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res (2000) 1.35
A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol (2004) 1.32
Continuous axenic cultivation of Pneumocystis carinii. Proc Natl Acad Sci U S A (1999) 1.29
Decreased and aberrant nuclear lamin expression in gastrointestinal tract neoplasms. Gut (1999) 1.25
RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther (1996) 1.24
Optimal N-ethyl-N-nitrosourea (ENU) doses for inbred mouse strains. Genesis (2000) 1.24
Identification and characterization of two nitrogen fixation regulatory regions, nifA and nfrX, in Azotobacter vinelandii and Azotobacter chroococcum. Mol Microbiol (1988) 1.22
Kaposi's sarcoma and new herpesvirus. Lancet (1995) 1.18
Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol (2004) 1.18
Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol (2007) 1.14
Linked markers flanking the gene for multiple endocrine neoplasia type 2A. Genomics (1989) 1.13
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer (2008) 1.12
Association study of the g.8818A>G polymorphism of the human agouti gene with melanoma risk and pigmentary characteristics in a French population. J Dermatol Sci (2005) 1.11
Relationship of airway wall thickening to an imbalance between matrix metalloproteinase-9 and its inhibitor in asthma. Thorax (2005) 1.10
Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Curr Cancer Drug Targets (2003) 1.09
Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cells. Cell Immunol (1999) 1.08
Cloning of the human erythropoietin receptor gene. Blood (1991) 1.08
Multiple risk factors in neonatal sinovenous thrombosis. Neurology (2002) 1.08
Natural history of dilated cardiomyopathy in children. Am Heart J (1991) 1.08
Assessing oncologic benefit in clinical trials of immunotherapy agents. Ann Oncol (2010) 1.07
Absence of human herpesvirus 8 sequences in prostate specimens. AIDS (1997) 1.07
Biological responses to porcine respiratory and reproductive syndrome virus in pigs of two genetic populations. J Anim Sci (2005) 1.05
Tissue specific expression of human erythropoietin receptor in transgenic mice. Dev Biol (1994) 1.05
Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res (1993) 1.05
Quantitative assessment of the spatial distribution of low attenuation areas on X-ray CT using texture analysis in patients with chronic pulmonary emphysema. Front Med Biol Eng (1997) 1.05
Molecular analysis of clonality in Kaposi's sarcoma. J Clin Pathol (1997) 1.05
Phase I trial of continuous infusion 5-aza-2'-deoxycytidine. Cancer Chemother Pharmacol (2003) 1.03
Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J Invest Dermatol (2001) 1.03
The nocturnal secretion of cardiac natriuretic peptides during obstructive sleep apnoea and its response to therapy with nasal continuous positive airway pressure. J Sleep Res (1998) 1.03
Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. Lab Invest (1996) 1.03
A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol (2007) 1.02
A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol (2007) 1.02
Tolerance of adjuvant letrozole outside of clinical trials. Breast (2008) 1.02
Two-phase liquid culture system models normal human adult erythropoiesis at the molecular level. Eur J Haematol (2000) 1.02
Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res (1998) 1.01
Antigen binding and idiotype analysis of antibodies obtained after electroporation of heavy and light chain genes encoding phosphocholine-specific antibodies: a model for T15-idiotype dominance. J Exp Med (1992) 1.01
Human herpes virus-8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d' Ile de France (GCIF). Transplantation (1999) 1.00
Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol (1994) 1.00
Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2'-deoxycytidine. Lancet (1984) 0.98
The impact of proband mediated information dissemination in families with a BRCA1/2 gene mutation. J Med Genet (2004) 0.98
Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer (2002) 0.97
Demonstration of two distinct subsets of gastric varices. Observations during a seven-year study of endoscopic sclerotherapy. Dig Dis Sci (1991) 0.96
Mitochondrial encephalomyopathy with A to G transition of mitochondrial transfer RNA(Leu(UUR)) 3,243 presenting hypertrophic cardiomyopathy. Intern Med (1995) 0.96
Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine. Antimicrob Agents Chemother (1995) 0.96
The development of gene therapy for the treatment of cancer. Ann Surg (1993) 0.95
LARG at chromosome 11q23 has functional characteristics of a tumor suppressor in human breast and colorectal cancer. Oncogene (2009) 0.95
Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome. Rheumatology (Oxford) (2007) 0.95
Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant (2005) 0.95
HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS (1999) 0.95
Epigenetic remodelling of DNA in cancer. Histol Histopathol (2007) 0.94
A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol (2013) 0.94
In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. J Biol Response Mod (1990) 0.93
Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine. Ann Hematol (2007) 0.93
Carbon monoxide: a hazard to fire fighters. Arch Environ Health (1979) 0.92
Identification of upstream regulatory elements that repress expression of adult beta-like globin genes in a primitive erythroid environment. Blood Cells Mol Dis (1998) 0.92
High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects. J Med Genet (1999) 0.92
Endoglin (CD105): a target for anti-angiogenetic cancer therapy. Curr Drug Targets (2003) 0.92
Clinical application of IL6 in cancer therapy. Res Immunol (1992) 0.92
Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother (1995) 0.91